Archive

Neovasc Provides Corporate Update

Posted on June 10, 2021
in
by

VANCOUVER and MINNEAPOLIS - June 10, 2021 -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Company has implemented a series of strategic initiatives focused on enhancing current shareholder value, minimizing dilution, extending its cash runaway well into 2024, focusing investments on near term value drivers, and more deeply reviewing the Company’s core business activities. Neovasc Reducer™The Company is focused on expanding reimbursement and increasing revenues in international...

Read More

Neovasc Reducer System Receives First National Reimbursement in Europe

Posted on June 7, 2021
in
by

NHS England Provides National CoverageVANCOUVER and MINNEAPOLIS - (NewMediaWire) - June 07, 2021 - Neovasc Inc. (Neovasc or the Company) (NASDAQ,TSX: NVCN) today announced that the Neovasc Reducer(R) (Reducer) system has been granted national reimbursement in England as a result of being included in the...

Read More

Neovasc Provides Update on German Litigation

Posted on May 20, 2021
in
by

VANCOUVER and MINNEAPOLIS - (NewMediaWire) - May 20, 2021 - Neovasc Inc. (Neovasc or the Company) (NASDAQ,TSX: NVCN) reported today that the Higher Regional Court in Munich, Germany has upheld the first instance judgment of the Regional Court Munich of June 16, 2017, in which...

Read More

Neovasc to Sponsor Symposium on Reducer at EuroPCR

Posted on May 13, 2021
in
by

VANCOUVER and MINNEAPOLIS - (NewMediaWire) - May 13, 2021 - Neovasc Inc. (Neovasc or the Company) (NASDAQ,TSX: NVCN) today announced that it will sponsor a symposium presenting the latest long-term clinical data on the Reducer(TM) (Reducer), highlighting its easy integration into current cardiovascular and microvascular...

Read More

Neovasc Announces First Patient Enrollment in COSIMA Trial

Posted on May 10, 2021
in
by

VANCOUVER and MINNEAPOLIS - (NewMediaWire) - May 10, 2021 - Neovasc Inc. (Neovasc or the Company) (NASDAQ,TSX: NVCN) today announced that the first patient has been enrolled in the COronary SInus Reducer for the Treatment of Refractory Microvascular Angina (COSIMA) trial. The enrollment occurred at University...

Read More

Neovasc Announces First Quarter 2021 Financial Results

Posted on May 6, 2021
in
by

VANCOUVER and MINNEAPOLIS - (NewMediaWire) - May 06, 2021 - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today reported financial results for the first quarter ended March 31, 2021. First Quarter HighlightsGenerated revenue of $451,794 in the quarter as Neovasc Reducer(TM) implants rebounded...

Read More